EYED PHARMA

{
  "facts": [
    {
      "type": "act_object",
      "quote": "Objet de l\u0027acte : CAPITAL, ACTIONS",
      "value": "CAPITAL, ACTIONS",
      "object": null,
      "subject": "e1"
    },
    {
      "type": "notarial_deed",
      "quote": "Il r\u00E9sulte d\u0027un acte re\u00E7u par Quentin PIRET, notaire associ\u00E9 \u00E0 Tilleur, le 24 avril 2026 que",
      "value": "2026-04-24",
      "object": "e2",
      "subject": "e1"
    },
    {
      "type": "general_meeting",
      "quote": "l\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire de la soci\u00E9t\u00E9 anonyme \u00AB EyeD PHARMA\u00BB... a pris \u00E0 l\u0027unanimit\u00E9 les r\u00E9solutions suivantes:",
      "value": "2026-04-24",
      "object": null,
      "subject": "e1"
    },
    {
      "type": "capital_decrease",
      "quote": "L\u2019Assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide, \u00E0 l\u2019unanimit\u00E9, de r\u00E9duire le capital \u00E0 concurrence de douze millions neuf cent septante-cinq mille septante-sept euros treize centimes (12.975.077,13 \u20AC), par incorporation, en vue d\u2019apurer \u00E0 concurrence du m\u00EAme montant, les pertes subies figurant \u00E0 la situation comptable arr\u00EAt\u00E9e au 31 d\u00E9cembre 2024 et approuv\u00E9e par l\u2019Assembl\u00E9e g\u00E9n\u00E9rale du 3 juillet 2025. En cons\u00E9quence, le capital est port\u00E9 de vingt-quatre millions huit cent quarante-sept mille neuf cent treize euros cinquante centimes (24.847.913,50 \u20AC) \u00E0 onze millions huit cent septante-deux mille huit cent trente-six euros trente-sept centimes (11.872.836,37 \u20AC). Cette r\u00E9duction de capital n\u2019entra\u00EEne aucun remboursement en faveur des actionnaires, ni aucune suppression d\u2019actions dont le nombre reste fix\u00E9 \u00E0 cinq millions six cent cinquante mille trente-neuf (5.650.039).",
      "value": {
        "delta": {
          "amount": -12975077.13,
          "currency": "EUR"
        },
        "reason": "apurement des pertes",
        "amount_after": {
          "amount": 11872836.37,
          "currency": "EUR"
        },
        "shares_after": 5650039,
        "amount_before": {
          "amount": 24847913.5,
          "currency": "EUR"
        },
        "share_classes": [
          {
            "class": "A",
            "count": 1338084
          },
          {
            "class": "B",
            "count": 183333
          },
          {
            "class": "C",
            "count": 966530
          },
          {
            "class": "D",
            "count": 3162092
          }
        ],
        "shares_before": 5650039
      },
      "object": null,
      "subject": "e1"
    },
    {
      "type": "statute_amendment",
      "quote": "l\u2019Assembl\u00E9e d\u00E9cide, \u00E0 l\u2019unanimit\u00E9, de remplacer le texte des articles 5 et 5bis des statuts par ce qui suit :",
      "value": "articles 5 et 5bis",
      "object": null,
      "subject": "e1"
    },
    {
      "type": "power_of_attorney",
      "quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale conf\u00E8re au notaire soussign\u00E9 tous pouvoirs n\u00E9cessaires aux fins de coordonner les statuts.",
      "value": "coordonner les statuts",
      "object": "e1",
      "subject": "e2"
    },
    {
      "type": "power_of_attorney",
      "quote": "L\u2019assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 Monsieur Marc FOIDART pour l\u2019ex\u00E9cution des r\u00E9solutions \u00E0 prendre sur les objets qui pr\u00E9c\u00E8dent.",
      "value": "ex\u00E9cution des r\u00E9solutions",
      "object": "e1",
      "subject": "e6"
    },
    {
      "type": "power_of_attorney",
      "quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale conf\u00E8re au notaire soussign\u00E9 tous pouvoirs n\u00E9cessaires aux fins d\u2019\u00E9tablir la liste des publications prescrites par le Code des soci\u00E9t\u00E9s et des associations.",
      "value": "formalit\u00E9s de publication",
      "object": "e1",
      "subject": "e2"
    },
    {
      "type": "filing",
      "quote": "D\u00E9pos\u00E9 24-04-2026",
      "value": "2026-04-24",
      "object": null,
      "subject": "e1"
    },
    {
      "type": "publication",
      "quote": "Bijlagen bij het Belgisch Staatsblad - 28/04/2026 - Annexes du Moniteur belge",
      "value": "2026-04-28",
      "object": null,
      "subject": "e1"
    },
    {
      "type": "incorporation",
      "quote": "Aux termes de l\u2019acte constitutif re\u00E7u par le notaire Michel CO\u00CBME, notaire associ\u00E9 \u00E0 Tilleur, en date du 14 d\u00E9cembre 2012, publi\u00E9 aux annexes du Moniteur Belge du 24 d\u00E9cembre suivant, r\u00E9f\u00E9rence 0306812, le capital social avait \u00E9t\u00E9 fix\u00E9 \u00E0 vingt mille euros (20.000 \u20AC).",
      "value": "2012-12-14",
      "object": "e3",
      "subject": "e1"
    },
    {
      "type": "founding_capital",
      "quote": "Aux termes du proc\u00E8s-verbal dress\u00E9 par le notaire Michel CO\u00CBME le 30 octobre 2013, l\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire des actionnaires a d\u00E9cid\u00E9 d\u2019augmenter le capital \u00E0 concurrence de cinq cent quatre-vingt mille euros (580.000,00 \u20AC) par apport en num\u00E9raire pour le porter de vingt mille euros (20.000,00 \u20AC) \u00E0 six cent mille euros (600.000,00 \u20AC), par la cr\u00E9ation de cinq cent quatre-vingt mille (580.000) nouvelles parts sociale sans d\u00E9signation de valeur nominale",
      "value": {
        "date": "2013-10-30",
        "amount": {
          "amount": 580000.0,
          "currency": "EUR"
        },
        "amount_after": {
          "amount": 600000.0,
          "currency": "EUR"
        },
        "amount_before": {
          "amount": 20000.0,
          "currency": "EUR"
        },
        "shares_created": 580000
      },
      "object": "e3",
      "subject": "e1"
    },
    {
      "type": "founding_capital",
      "quote": "Aux termes du proc\u00E8s-verbal dress\u00E9 par le notaire Michel CO\u00CBME le 22 juin 2016, l\u2019assembl\u00E9e g\u00E9n\u00E9rale extraordinaire a d\u00E9cid\u00E9 d\u2019augmenter le capital \u00E0 concurrence de un million neuf cent soixante-sept mille cinq (1.967.500,00 \u20AC) pour porter celui-ci de six cent mille euros (600.000,00 \u20AC), \u00E0 deux millions cinq cent soixante-sept mille cinq cent euros (2.567.500,00 \u20AC), par la cr\u00E9ation de trois cent nonante-trois mille cinq cent (393.500) nouvelles actions",
      "value": {
        "date": "2016-06-22",
        "amount": {
          "amount": 1967500.0,
          "currency": "EUR"
        },
        "amount_after": {
          "amount": 2567500.0,
          "currency": "EUR"
        },
        "amount_before": {
          "amount": 600000.0,
          "currency": "EUR"
        },
        "shares_created": 393500
      },
      "object": "e3",
      "subject": "e1"
    },
    {
      "type": "founding_capital",
      "quote": "Aux termes du proc\u00E8s-verbal dress\u00E9 par la notaire Manon DEPREZ le 3 juillet 2018, l\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire a d\u00E9cid\u00E9 d\u2019augmenter le capital \u00E0 concurrence de deux million cinq cent soixante-sept mille cinq cents euros (2.567.500,00 \u20AC) pour porter celui-ci de deux millions cinq cent soixante-sept mille cinq cent euros (2.567.500,00 \u20AC), \u00E0 cinq million cent trente-cinq mille euros (5.135.000,00 \u20AC), par la cr\u00E9ation de quatre cent vingt-sept mille neuf cent dix-sept (427.917) nouvelles actions",
      "value": {
        "date": "2018-07-03",
        "amount": {
          "amount": 2567500.0,
          "currency": "EUR"
        },
        "amount_after": {
          "amount": 5135000.0,
          "currency": "EUR"
        },
        "amount_before": {
          "amount": 2567500.0,
          "currency": "EUR"
        },
        "shares_created": 427917
      },
      "object": "e4",
      "subject": "e1"
    },
    {
      "type": "founding_capital",
      "quote": "Aux termes du proc\u00E8s-verbal dress\u00E9 par la notaire Manon DEPREZ, le 9 mai 2019, l\u2019assembl\u00E9e g\u00E9n\u00E9rale a d\u00E9cid\u00E9 d\u2019augmenter le capital \u00E0 concurrence de quatre million cent sept mille sept cent cinquante euros (4.107.750,00 \u20AC) pour porter celui-ci de cinq million cent trente-cinq mille euros (5.135.000,00 \u20AC), \u00E0 neuf million deux cents quarante-deux mille sept cent cinquante euros (9.242.750,00 \u20AC), par la cr\u00E9ation de quatre cent quatre-vingt-trois mille deux cent soixante-onze (483.271) nouvelles actions, de classe C",
      "value": {
        "date": "2019-05-09",
        "amount": {
          "amount": 4107750.0,
          "currency": "EUR"
        },
        "share_class": "C",
        "amount_after": {
          "amount": 9242750.0,
          "currency": "EUR"
        },
        "amount_before": {
          "amount": 5135000.0,
          "currency": "EUR"
        },
        "shares_created": 483271
      },
      "object": "e4",
      "subject": "e1"
    },
    {
      "type": "capital_decrease",
      "quote": "Aux termes du proc\u00E8s-verbal dress\u00E9 par la notaire Manon DEPREZ, le 30 octobre 2019, l\u2019assembl\u00E9e g\u00E9n\u00E9rale a d\u00E9cid\u00E9 de proc\u00E9der \u00E0 une scission partielle de la soci\u00E9t\u00E9, entra\u00EEnant une r\u00E9duction de son capital \u00E0 concurrence d\u2019un million trois cent six mille cinq cent quarante et un euros et vingt-trois centimes (1.306.541,23 \u20AC). Le capital de la SA EYED PHARMA a ainsi \u00E9t\u00E9 r\u00E9duit \u00E0 sept millions neuf cent trente-six mille deux cent huit euros et septante-sept centimes (7.936.208,77 \u20AC).",
      "value": {
        "date": "2019-10-30",
        "amount": {
          "amount": 1306541.23,
          "currency": "EUR"
        },
        "reason": "scission partielle",
        "amount_after": {
          "amount": 7936208.77,
          "currency": "EUR"
        },
        "amount_before": {
          "amount": 9242750.0,
          "currency": "EUR"
        }
      },
      "object": "e4",
      "subject": "e1"
    },
    {
      "type": "founding_capital",
      "quote": "Aux termes du proc\u00E8s-verbal dress\u00E9 par la notaire Manon DEPREZ, le 30 octobre 2019, l\u2019assembl\u00E9e g\u00E9n\u00E9rale a d\u00E9cid\u00E9 d\u2019augmenter le capital \u00E0 concurrence trois millions neuf cent quatre mille sept cent trente-deux euros septante-trois centimes (3.904.732,73 \u20AC) pour porter celui-ci de sept millions neuf cent trente-six mille deux cent huit euros et septante-sept centimes (7.936.208,77 \u20AC), \u00E0 onze millions huit cent quarante mille neuf cent quarante-et-un euros cinquante centimes (11.840.941,50 \u20AC), par la cr\u00E9ation de quatre cent quatre-vingt-trois mille deux cent cinquante-neuf (483.259) nouvelles actions, de classe C",
      "value": {
        "date": "2019-10-30",
        "amount": {
          "amount": 3904732.73,
          "currency": "EUR"
        },
        "share_class": "C",
        "amount_after": {
          "amount": 11840941.5,
          "currency": "EUR"
        },
        "amount_before": {
          "amount": 7936208.77,
          "currency": "EUR"
        },
        "shares_created": 483259
      },
      "object": "e4",
      "subject": "e1"
    },
    {
      "type": "capital_increase",
      "quote": "Aux termes d\u2019un acte re\u00E7u par la notaire Anne MICHEL, le 6 avril 2021, il a \u00E9t\u00E9 constat\u00E9 \u00E0 la conversion de cent mille (100.000) droits de souscription en cent mille (100.000) actions de classe A, et \u00E0 l\u2019augmentation du capital \u00E0 concurrence de cent mille euros (100.000 EUR).",
      "value": {
        "date": "2021-04-06",
        "amount": {
          "amount": 100000.0,
          "currency": "EUR"
        },
        "reason": "conversion de droits de souscription",
        "share_class": "A",
        "shares_created": 100000
      },
      "object": "e5",
      "subject": "e1"
    },
    {
      "type": "founding_capital",
      "quote": "Aux termes du proc\u00E8s-verbal dress\u00E9 par la notaire Michel CO\u00CBME, le 20 d\u00E9cembre 2021, l\u2019assembl\u00E9e g\u00E9n\u00E9rale a d\u00E9cid\u00E9 d\u2019augmenter le capital \u00E0 concurrence quinze millions neuf cent septante mille trois cent cinquante-huit euros (15.970.358 \u20AC) pour porter celui-ci de onze millions neuf cent quarante mille neuf cent quarante-et-un euros cinquante centimes (11.940.941,50 \u20AC), \u00E0 vingt-sept millions neuf cent onze mille deux cent nonante-neuf euros cinquante centimes (27.911.299,50 \u20AC), par la cr\u00E9ation de un million cinq cent quatre-vingt-un mille quarante-six (1.581.046) nouvelles actions, de classe D",
      "value": {
        "date": "2021-12-20",
        "amount": {
          "amount": 15970358.0,
          "currency": "EUR"
        },
        "share_class": "D",
        "amount_after": {
          "amount": 27911299.5,
          "currency": "EUR"
        },
        "amount_before": {
          "amount": 11940941.5,
          "currency": "EUR"
        },
        "shares_created": 1581046
      },
      "object": "e3",
      "subject": "e1"
    },
    {
      "type": "founding_capital",
      "quote": "Aux termes du proc\u00E8s-verbal dress\u00E9 par Manon DEPREZ, pr\u00E9cit\u00E9e, le 20 janvier 2023, l\u2019assembl\u00E9e g\u00E9n\u00E9rale a d\u00E9cid\u00E9 d\u2019augmenter le capital \u00E0 concurrence quinze millions neuf cent septante mille trois cent cinquante-huit euros (15.970.358 \u20AC) pour porter celui-ci de vingt-sept millions neuf cent onze mille deux cent nonante-neuf euros cinquante centimes (27.911.299,50 \u20AC), \u00E0 quarante-trois millions huit cent quatre-vingt-un mille six cent cinquante-sept euros cinquante centimes (43.881.657,50 \u20AC), par la cr\u00E9ation de un million cinq cent quatre-vingt-un mille quarante-six (1.581.046) nouvelles actions, de classe D",
      "value": {
        "date": "2023-01-20",
        "amount": {
          "amount": 15970358.0,
          "currency": "EUR"
        },
        "share_class": "D",
        "amount_after": {
          "amount": 43881657.5,
          "currency": "EUR"
        },
        "amount_before": {
          "amount": 27911299.5,
          "currency": "EUR"
        },
        "shares_created": 1581046
      },
      "object": "e4",
      "subject": "e1"
    },
    {
      "type": "capital_decrease",
      "quote": "Aux termes d\u2019un acte re\u00E7u par Manon DEPREZ, notaire associ\u00E9e \u00E0 Tilleur, le 20 novembre 2023, l\u2019assembl\u00E9e g\u00E9n\u00E9rale a d\u00E9cid\u00E9 de r\u00E9duire le capital \u00E0 concurrence dix neuf millions trente-trois mille sept cent quarante-quatre euros (19.033.744,00 \u20AC), par apurement, \u00E0 concurrence du m\u00EAme montant, des pertes report\u00E9es figurant \u00E0 la situation comptable arr\u00EAt\u00E9e au 31 d\u00E9cembre 2022, en vue de le porter de quarante-trois millions huit cent quatre-vingt-un mille six cent cinquante-sept euros cinquante centimes (43.881.657,50 \u20AC) \u00E0 vingt-quatre millions huit cent quarante-sept mille neuf cent treize euros cinquante centimes (24.847.913,50 \u20AC).",
      "value": {
        "date": "2023-11-20",
        "amount": {
          "amount": 19033744.0,
          "currency": "EUR"
        },
        "reason": "apurement des pertes report\u00E9es",
        "amount_after": {
          "amount": 24847913.5,
          "currency": "EUR"
        },
        "amount_before": {
          "amount": 43881657.5,
          "currency": "EUR"
        }
      },
      "object": "e4",
      "subject": "e1"
    }
  ],
  "act_meta": {
    "model_id": 40,
    "extractor": "open-capture-27b-v3",
    "ocr_chars": 14768,
    "truncated": false,
    "needs_verify": true
  },
  "entities": [
    {
      "id": "e1",
      "kbo": "0508.599.605",
      "kind": "company",
      "name": "EyeD PHARMA",
      "attrs": {
        "seat": "Rue Louis Plescia 9, 4102 Seraing",
        "legal_form": "Soci\u00E9t\u00E9 anonyme"
      }
    },
    {
      "id": "e2",
      "kbo": null,
      "kind": "person",
      "name": "Quentin PIRET",
      "attrs": {
        "role": "notaire associ\u00E9 \u00E0 Tilleur"
      }
    },
    {
      "id": "e3",
      "kbo": null,
      "kind": "person",
      "name": "Michel CO\u00CBME",
      "attrs": {
        "role": "notaire associ\u00E9 \u00E0 Tilleur"
      }
    },
    {
      "id": "e4",
      "kbo": null,
      "kind": "person",
      "name": "Manon DEPREZ",
      "attrs": {
        "role": "notaire associ\u00E9e \u00E0 Tilleur"
      }
    },
    {
      "id": "e5",
      "kbo": null,
      "kind": "person",
      "name": "Anne MICHEL",
      "attrs": {
        "role": "notaire"
      }
    },
    {
      "id": "e6",
      "kbo": null,
      "kind": "person",
      "name": "Marc FOIDART",
      "attrs": {
        "role": "mandataire pour l\u0027ex\u00E9cution des r\u00E9solutions"
      }
    }
  ]
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Pierre BELICHARD",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2025-04-23",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale nomme, \u00E0 la majorit\u00E9 des voix \u00E9mises, Monsieur Pierre BELICHARD en qualit\u00E9 d\u0027administrateur ind\u00E9pendant, avec effet au 23 avril 2025."
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Robert TAUB",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2024-12-15",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale nomme, \u00E0 la majorit\u00E9 des voix \u00E9mises, Monsieur Robert TAUB en qualit\u00E9 d\u0027administrateur de classe C, avec effet au 15 d\u00E9cembre 2024."
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Jean-Philippe COMBAL",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2025-07-03",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale nomme, \u00E0 la majorit\u00E9 des voix \u00E9mises Monsieur Jean-Philippe COMBAL en qualit\u00E9 d\u0027administrateur ind\u00E9pendant, avec effet \u00E0 ce jour."
    },
    {
      "kind": "director_renew",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Marc FOIDART",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2025-07-03",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide, \u00E0 la majorit\u00E9 des voix \u00E9mises, de renouveler les mandats de Monsieur Marc FOIDART en qualit\u00E9 d\u0027administrateur de classe A ... et ce avec effet \u00E0 ce jour."
    },
    {
      "kind": "director_renew",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Jean-Marie RAKIC",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2025-07-03",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide, \u00E0 la majorit\u00E9 des voix \u00E9mises, de renouveler les mandats de ... Monsieur Jean-Marie RAKIC en qualit\u00E9 d\u0027administrateur de classe A ... et ce avec effet \u00E0 ce jour."
    },
    {
      "kind": "director_renew",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Eric BRANDT",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "NOSHAQ SA",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2025-07-03",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide, \u00E0 la majorit\u00E9 des voix \u00E9mises, de renouveler les mandats de ... la SA NOSHAQ en qualit\u00E9 d\u0027administrateur de classe B, et ce avec effet \u00E0 ce jour."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2023-11-20",
    "legal_form_change": false
  },
  "bedrijfsrevisor": {
    "quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de nommer, \u00E0 la fonction de commissaire, la soci\u00E9t\u00E9 BDO EXPERTS COMPTABLES \u0026 CONSEILLERS FISCAUX, en abr\u00E9g\u00E9 BDO Experts Comptables, dont le si\u00E8ge est situ\u00E9 \u00E0 1930 Zaventem, Da Vincilaan 9 bo\u00EEte E.6, avec un si\u00E8ge d\u2019exploitation \u00E0 4651 Herve (Battice), Rue Waucomont 51, repr\u00E9sent\u00E9e par Monsieur C\u00E9dric ANTONELLI, pour une dur\u00E9e de 3 ans, renouvelable.",
    "firm_kbo": null,
    "firm_name": "BDO EXPERTS COMPTABLES \u0026 CONSEILLERS FISCAUX",
    "ibr_number": null,
    "individual_name": "C\u00E9dric ANTONELLI"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  },
  "signature_regime": null,
  "special_mandates": [
    {
      "quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale conf\u00E8re au notaire soussign\u00E9 tous pouvoirs n\u00E9cessaires aux fins de coordonner les statuts.",
      "holder_kbo": null,
      "holder_name": "notaire soussign\u00E9",
      "scope_categories": [
        "publication",
        "coordination"
      ],
      "with_substitution": false
    },
    {
      "quote": "L\u2019assembl\u00E9e conf\u00E8re tous pouvoirs \u00E0 Monsieur Marc FOIDART pour l\u2019ex\u00E9cution des r\u00E9solutions \u00E0 prendre sur les objets qui pr\u00E9c\u00E8dent.",
      "holder_kbo": null,
      "holder_name": "Marc FOIDART",
      "scope_categories": [
        "execution"
      ],
      "with_substitution": false
    }
  ],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Jean Van Nuwenborg",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0668403244",
        "name": "Qbic Venture Partner II NV",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2022-07-14",
      "evidence_quote": "La repr\u00E9sentante permanente de l\u0027Administrateur de classe C Qbic Venture Partner II NV, Hekers 3, 9051 Zwijnaarde avec le num\u00E9ro d\u0027entreprise 0668.403.244, devient \u00E0 partir du 14 juillet 2022, Mme Sofie Baeten, en remplacement de M. Jean Van Nuwenborg."
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Sofie Baeten",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0668403244",
        "name": "Qbic Venture Partner II NV",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2022-07-14",
      "evidence_quote": "La repr\u00E9sentante permanente de l\u0027Administrateur de classe C Qbic Venture Partner II NV, Hekers 3, 9051 Zwijnaarde avec le num\u00E9ro d\u0027entreprise 0668.403.244, devient \u00E0 partir du 14 juillet 2022, Mme Sofie Baeten, en remplacement de M. Jean Van Nuwenborg."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Lawrence VAN HELLEPUTTE",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0629896521",
        "name": "Soci\u00E9t\u00E9 Anonyme \u00AB FUND\u002B \u00BB",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide en cons\u00E9quence de proc\u00E9der \u00E0 la nomination, en qualit\u00E9 d\u2019 administrateur de classe C : \u2022 La Soci\u00E9t\u00E9 Anonyme \u00AB FUND\u002B \u00BB, ayant son si\u00E8ge \u00E0 3000 Louvain, Groot Begijnhof 60, bo\u00EEte 1, reprise au registre des personnes morales sous le num\u00E9ro 0629.896.521, pour laquelle Monsieu"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "zetel_transfer",
      "seat_type": "statutaire",
      "new_address": {
        "city": "Seraing",
        "region": null,
        "street": "rue Louis Plescia",
        "country": "BE",
        "postcode": "4102",
        "box_number": null,
        "street_number": "9"
      },
      "old_address": {
        "city": "Li\u00E8ge",
        "region": null,
        "street": "Avenue Hippocrate",
        "country": "BE",
        "postcode": "4000",
        "box_number": null,
        "street_number": "5"
      },
      "effective_date": "2022-03-24",
      "evidence_quote": "En sa s\u00E9ance du 24 mars 2022, le conseil d\u0027administration a d\u00E9cid\u00E9, \u00E0 l\u0027unanimit\u00E9, de transf\u00E9rer le si\u00E8ge de la soci\u00E9t\u00E9 \u00E0 l\u0027adresse suivante: rue Louis Plescia, 9 \u00E0 4102 Seraing (Ougr\u00E9e)."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 100000,
      "currency": "EUR",
      "after_eur": 11940941.5,
      "delta_eur": 100000.0,
      "before_eur": 11840941.5,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2021-04-06",
      "evidence_quote": "De la sorte, le capital de la soci\u00E9t\u00E9 est augment\u00E9 \u00E0 concurrence de cent mille euros (100.000 \u20AC), pour porter celui-ci de onze millions huit cent quarante mille neuf cent quarante-et-un euros cinquante centimes (11.840.941,50 \u20AC) \u00E0 onze millions neuf cent quarante mille neuf cent quarante-et-un euros cinquante centimes (11.940.941,50 \u20AC).",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 3904732.73,
      "currency": "EUR",
      "after_eur": 11840941.5,
      "delta_eur": 3904732.73,
      "before_eur": 7936208.77,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2019-09-30",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide d\u0027augmenter le capital social \u00E0 concurrence de trois millions neuf cent quatre mille sept cent trente-deux euros septante-trois centimes (3.904.732,73 \u20AC) pour porter celui-ci de sept millions neuf cent trente-six mille deux cent huit euros et septante-sept centimes (7.936.208,77 \u20AC), \u00E0 onze millions huit cent quarante mille neuf cent quarante-et-un euros cinquante centimes (11.840.941,50 \u20AC)",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_decrease",
      "amount": 1306541.23,
      "currency": "EUR",
      "after_eur": 7936208.77,
      "delta_eur": -1306541.23,
      "before_eur": 9242750.0,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2019-10-30",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale constate que le capital social est r\u00E9duit \u00E0 concurrence de un million trois cent six mille cinq cent quarante et un euros et vingt-trois centimes (1.306.541,23 \u20AC), par l\u0027effet de la scission partielle aprouv\u00E9e aux pr\u00E9c\u00E9dentes r\u00E9solutions. Le capital de la SA EYED PHARMA de neuf millions deux cent quarante-deux mille sept cent cinquante euros (9.242.750,00 \u20AC) est r\u00E9duit \u00E0 sept millions neuf cent trente-six mille deu cent huit euros et septante-sept centimes (7.936.208,77 \u20AC)",
      "contribution_type": null
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "stage": "proposal",
  "notary": {
    "name": "Rapha\u00EBl DOUNY",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Li\u00E8ge",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2019-09-12",
    "filing_date": "1975-12-05",
    "act_kind_objet": ""
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2019-08-30",
    "unanimous": true
  },
  "conversion": null,
  "detected_kind": "demerger_partial",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0508.599.605",
        "name": "EYED PHARMA",
        "role": "demerged",
        "address": "Avenue Hippocrate 5, 4000 Li\u00E8ge",
        "is_foreign": false,
        "legal_form": "S.A.",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": null,
        "name": "UniD Manufacturing",
        "role": "recipient",
        "address": "Avenue Hippocrate 5, 4000 Li\u00E8ge",
        "is_foreign": false,
        "legal_form": "S.A.",
        "is_new_company": true,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "12:74",
      "12:75",
      "12:76",
      "12:85"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2019-06-30",
    "exchange_ratio_text": null,
    "new_shares_issued_n": 1904688,
    "real_estate_included": false,
    "patrimony_description": "Le transfert concerne l\u0027ensemble des \u00E9l\u00E9ments li\u00E9s \u00E0 la production d\u0027implants oculaires, notamment les \u00E9quipements de production en location-financement, les acomptes vers\u00E9s pour du mat\u00E9riel de production, certains outillages sp\u00E9cifiques, du mat\u00E9riel de bureau, ainsi que les passifs li\u00E9s \u00E0 ces actifs. L\u0027activit\u00E9 commerciale, la recherche et le d\u00E9veloppement dans le domaine ophtalmologique, et les ",
    "equity_transferred_eur": 800000.0,
    "accounting_effective_date": "2019-07-01"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "S.A."
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": null,
    "org_name": "Ma\u00EEtre Rapha\u00EBl DOUNY, avocat de l\u0027\u00E9tude MATRAY, MATRAY et HALLET SC",
    "person_name": null,
    "org_rep_person_name": "Rapha\u00EBl DOUNY"
  },
  "summary_narrative": "Le conseil d\u0027administration de la soci\u00E9t\u00E9 anonyme EYED PHARMA a d\u00E9cid\u00E9 d\u0027\u00E9tablir un projet de scission partielle, visant \u00E0 transf\u00E9rer les activit\u00E9s de production d\u0027implants oculaires, ainsi que les \u00E9quipements et passifs associ\u00E9s, vers une nouvelle soci\u00E9t\u00E9 \u00E0 constituer, UniD Manufacturing. Cette op\u00E9ration, fond\u00E9e sur l\u0027article 12:74 du Code des Soci\u00E9t\u00E9s et des Associations, vise \u00E0 s\u00E9parer les activit\u00E9s de production des activit\u00E9s de recherche et de commercialisation, afin de lib\u00E9rer la soci\u00E9t\u00E9 scind\u00E9e de charges li\u00E9es \u00E0 la production. Les actionnaires de la soci\u00E9t\u00E9 scind\u00E9e recevront des parts ",
  "co_filed_documents": [
    "Projet de statuts de la nouvelle soci\u00E9t\u00E9 issue de la scission",
    "Projet des premi\u00E8res dispositions transitoires",
    "Rapport du r\u00E9viseur d\u0027entreprises REWISE AD REVISEUR D\u0027ENTREPRISES SOPRL"
  ],
  "detected_real_type": "demerger_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2019-06-13",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  },
  "signature_regime": "joint_two",
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 2567500.0,
      "currency": "EUR",
      "after_eur": 5135000.0,
      "delta_eur": 2567500.0,
      "before_eur": 2567500.0,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2018-07-03",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide d\u2019augmenter le capital social \u00E0 concurrence de deux million cinq cent soixante-sept mille cinq cents euros (2.567.500,00 \u20AC) pour porter celui-ci de deux millions cinq cent soixante-sept mille cinq cent euros (2.567.500,00 \u20AC), \u00E0 cinq million cent trente-cinq mille euros (5.135.000,00 \u20AC)",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Fran\u00E7oise Leblanc",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "SA Soci\u00E9t\u00E9 d\u0027Investissement et de Participation du Bassin de Li\u00E8ge",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "Par cons\u00E9quent, la nomination de la SA Soci\u00E9t\u00E9 d\u0027Investissement et de Participation du Bassin de Li\u00E8ge (Administrateur), dont Fran\u00E7oise Leblanc est le repr\u00E9sentant permanent, est approuv\u00E9e."
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Henri Lema\u00EEtre",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "Par cons\u00E9quent, la nomination de Monsieur Henri Lema\u00EEtre (Administrateur) est approuv\u00E9e."
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Jean-Michel Foidart",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "Par cons\u00E9quent, la nomination de Monsieur Jean-Michel Foidart (Administrateur) est approuv\u00E9e."
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Sprl Mercury Leadership and Management",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "Par cons\u00E9quent, la nomination de la Sprl Mercury Leadership and Management (Administrateur) est approuv\u00E9e."
    },
    {
      "kind": "director_renew",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Marc Foidart",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "Par cons\u00E9quent, le renouvellement du mandat de Monsieur Marc Foidart (Administrateur) est approuv\u00E9."
    },
    {
      "kind": "director_renew",
      "role": "gedelegeerd_bestuurder",
      "person": {
        "rrn": null,
        "name": "Sprl Biofinance Consulting",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "Par cons\u00E9quent, le renouvellement du mandat de la Sprl Biofinance Consulting (Administrateur d\u00E9l\u00E9gu\u00E9) est approuv\u00E9."
    },
    {
      "kind": "director_renew",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Jean-Marie Rakic",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "Par cons\u00E9quent, le renouvellement du mandat de Monsieur Jean-Marie Rakic (Pr\u00E9sident du Conseil d\u0027Adm.) est approuv\u00E9."
    },
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Marc Foidart",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "Sprl OUSIA",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "Par cons\u00E9quent, la r\u00E9vocation de la Spri Ousia (Administrateur), dont Marc Foidart est le repr\u00E9sentant permanent, est approuv\u00E9e."
    },
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Christine J\u00E9r\u00F4me",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "Par cons\u00E9quent, la r\u00E9vocation de Madame Christine J\u00E9r\u00F4me (Administrateur) est approuv\u00E9e."
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Spri Oukelos",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "Par cons\u00E9quent, la nomination de la Spri Oukelos (Administrateur) est approuv\u00E9e."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 1967500.0,
      "currency": "EUR",
      "after_eur": 2567500.0,
      "delta_eur": 1967500.0,
      "before_eur": 600000.0,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2016-06-22",
      "evidence_quote": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide d\u0027augmenter le capital social \u00E0 concurrence un million neuf cent soixante-sept mille cinq cent (1.967.500,00 \u20AC) pour porter celui-ci de six cent mille euros (600.000,00 \u20AC), \u00E0 deux millions cing cent soixante-sept mille cing cent euros (2.567.500,00 \u20AC)",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Marc Foidart",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "L\u0027assembl\u00E9e se prononce sur la nomination de Monsieur Marc Foidart en tant qu\u0027administrateur jusqu\u0027\u00E0 l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire de 2019. ... Par cons\u00E9quent, la nomination de Monsieur Marc Foidart en tant qu\u0027administrateur est approuv\u00E9e."
    },
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "SPRL Majocepi",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "L\u0027assembl\u00E9e se prononce sur la r\u00E9vocation du mandat d\u0027administrateur de la SPRL Majocepi. ... Par cons\u00E9quent, la r\u00E9vocation de la SPRL Majocepi (Administrateur) est approuv\u00E9e."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SA"
  }
}

{
  "events": [
    {
      "kind": "zetel_transfer",
      "seat_type": "statutaire",
      "new_address": {
        "city": "Li\u00E8ge",
        "region": null,
        "street": "Avenue Hippocrate",
        "country": "BE",
        "postcode": "4000",
        "box_number": null,
        "street_number": "5"
      },
      "old_address": {
        "city": "Li\u00E8ge",
        "region": null,
        "street": "Rue des Augustins",
        "country": "BE",
        "postcode": "4000",
        "box_number": null,
        "street_number": "17"
      },
      "effective_date": "2015-06-06",
      "evidence_quote": "Transfert du si\u00E8ge social ... Madame MESTDAG M\u00E9lanie propose de transf\u00E9rer le si\u00E8ge social \u00E0 l\u0027adresse suivante: Quartier H\u00F4pital Avenue Hippocrate 5 4000 Li\u00E8ge"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0508.599.605",
    "name_full": "EYED PHARMA",
    "legal_form": "SPRL"
  }
}